Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest Down 21.8% in February

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) saw a large drop in short interest in February. As of February 27th, there was short interest totaling 57,707 shares, a drop of 21.8% from the February 12th total of 73,787 shares. Based on an average daily volume of 59,146 shares, the short-interest ratio is currently 1.0 days. Currently, 2.8% of the shares of the stock are sold short. Currently, 2.8% of the shares of the stock are sold short. Based on an average daily volume of 59,146 shares, the short-interest ratio is currently 1.0 days.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Wednesday, January 21st. Wall Street Zen upgraded shares of Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 28th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Acurx Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $31.00.

Acurx Pharmaceuticals Stock Down 22.6%

NASDAQ:ACXP opened at $3.88 on Monday. The stock has a fifty day simple moving average of $2.39 and a 200 day simple moving average of $3.80. The firm has a market capitalization of $11.10 million, a price-to-earnings ratio of -0.69 and a beta of -1.16. Acurx Pharmaceuticals has a 1-year low of $1.33 and a 1-year high of $21.00.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($1.01) by $0.70. Equities analysts predict that Acurx Pharmaceuticals will post -0.89 earnings per share for the current year.

Hedge Funds Weigh In On Acurx Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new stake in Acurx Pharmaceuticals during the 4th quarter valued at $27,000. Geode Capital Management LLC acquired a new stake in shares of Acurx Pharmaceuticals in the fourth quarter worth $31,000. Millennium Management LLC acquired a new stake in shares of Acurx Pharmaceuticals in the fourth quarter worth $103,000. Finally, Armistice Capital LLC purchased a new position in shares of Acurx Pharmaceuticals during the second quarter valued at $551,000. Institutional investors and hedge funds own 11.53% of the company’s stock.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).